Short Interest in TransCode Therapeutics Inc. (NASDAQ:RNAZ) Grows By 100.9%

TransCode Therapeutics Inc. (NASDAQ:RNAZ) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 56,527 shares, a growth of 100.9% from the May 31st total of 28,142 shares. Based on an average daily trading volume, of 230,735 shares, the short-interest ratio is presently 0.2 days. Approximately 6.0% of the company’s shares are short sold.

TransCode Therapeutics Stock Up 8.0%

NASDAQ RNAZ traded up $0.61 on Thursday, reaching $8.27. The company had a trading volume of 18,973 shares, compared to its average volume of 150,954. The stock’s 50 day moving average is $6.26 and its 200-day moving average is $8.02. The stock has a market cap of $7.85 million, a price-to-earnings ratio of -0.16 and a beta of 1.22. TransCode Therapeutics has a 52 week low of $3.82 and a 52 week high of $20.99.

TransCode Therapeutics (NASDAQ:RNAZ) last released its earnings results on Friday, May 15th. The company reported ($21.28) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TransCode Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.